Correlation of the TCR Diversity Indexes in the Peripheral Blood with Disease Susceptibility and Deterioration in COVID-19 Patients
Yue Zhuo,Ji-Yuan Zhang,Zhen Zhang,Lifeng Zhang,Xin Yang,Jin-Wen Song,Xuan Zhao,Jianmin Huang,Xing Fan,Ping Shuai,Xueping Wen,Xuemei Zhong,Jian Xiao,Hong Liu,Xiao-Peng Dai,Peng Xia,Lihua Xing,Mengying Yao,Qiuge Wu,Hongxia Liang,Zhiqiang Zhu,Yi Kang,XiaoLu Luo,Zeduan Liu,Yaofeng Wu,Yunchao Wang,Wanqiu Huang,Liang Wei,Xiaobo Huang,Liping Liu,Jian Huang,Shaoping Deng,Jing Leng,Yi Zhang,Fu-Sheng Wang,Zhixin Zhang
DOI: https://doi.org/10.2139/ssrn.4115777
2022-01-01
SSRN Electronic Journal
Abstract:The 2019 coronavirus disease (COVID-19) caused by SARS-CoV-2 infection has become a global pandemic for more than two years. SARS-CoV-2 infection caused different clinical results, from none or mild symptoms to life threatening pneumonia. The determining factors for such discrepancy outcome are still not very clear. Accumulating studies suggest that the potency of the immune system in each individual has important influence on the clinical outcomes upon SARS-CoV-2 infection. Using high through put sequencing, we analyzed the expressed TCRβ repertoire in the peripheral blood of hospitalized mild and severe COVID-19 patients, cured COVID-19 patients and healthy donors. There are significant changes in the TCRβ repertoire upon viral infection compared to healthy donors and distinct features between mild and severe patients. All the COVID-19 patients had significantly lower TCR diversity indexes and significantly higher frequency of large oligo TCR clones compared to those in the healthy donors; the severe patients had significantly lower TCR diversity indexes and significantly higher frequencies of large oligo TCR clones compared to those in the mild patients. These results emphasize the significant role of T cells in anti-SARS-CoV-2 response and indicate that the TCR diversity index of each individual may be used as a novel predictor for disease susceptibility and deterioration upon SARS-CoV2 infection.Funding Information: This study was supported by COVID-19 Emergency Research Fund from Sichuan(2020YFS0016, ZZ), Henan (No. 201100310900, YZ), and Guangxi (GuiKe AB20072005, JL) provinces. Sample preparation, high-through-put TCRβ sequencing, data analyses were performed by the Chengdu ExAb Biotechnology Ltd.Declaration of Interests: ZZ is the founder of Chengdu ExAb Biotechnology Ltd. Other authors had no competing interests.Ethics Approval Statement: All experiments using human samples were approved by the Ethics Committees of Sichuan Provincial Peoples Hospital (No: 2020-97), Fifth Medical Center of Chinese PLA General Hospital, The First Affiliated Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhoukou Infectious Disease Hospital, and The Fourth People's Hospital of Nanning. Informed consent was obtained from every participant.